196 related articles for article (PubMed ID: 24989892)
1. Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831.
Norton N; Olson RM; Pegram M; Tenner K; Ballman KV; Clynes R; Knutson KL; Perez EA
Cancer Immunol Res; 2014 Oct; 2(10):962-9. PubMed ID: 24989892
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.
Hurvitz SA; Betting DJ; Stern HM; Quinaux E; Stinson J; Seshagiri S; Zhao Y; Buyse M; Mackey J; Driga A; Damaraju S; Sliwkowski MX; Robert NJ; Valero V; Crown J; Falkson C; Brufsky A; Pienkowski T; Eiermann W; Martin M; Bee V; Marathe O; Slamon DJ; Timmerman JM
Clin Cancer Res; 2012 Jun; 18(12):3478-86. PubMed ID: 22504044
[TBL] [Abstract][Full Text] [Related]
3. Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial.
Gavin PG; Song N; Kim SR; Lipchik C; Johnson NL; Bandos H; Finnigan M; Rastogi P; Fehrenbacher L; Mamounas EP; Swain SM; Wickerham DL; Geyer CE; Jeong JH; Costantino JP; Wolmark N; Paik S; Pogue-Geile KL
JAMA Oncol; 2017 Mar; 3(3):335-341. PubMed ID: 27812689
[TBL] [Abstract][Full Text] [Related]
4. ABCB1, FCGR2A, and FCGR3A polymorphisms in patients with HER2-positive metastatic breast cancer who were treated with first-line taxane plus trastuzumab chemotherapy.
Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Han SW; Jeon YK; Oh DY; Han W; Kim TY; Park IA; Noh DY; Bang YJ
Oncology; 2012; 83(4):218-27. PubMed ID: 22906996
[TBL] [Abstract][Full Text] [Related]
5. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.
Roca L; Diéras V; Roché H; Lappartient E; Kerbrat P; Cany L; Chieze S; Canon JL; Spielmann M; Penault-Llorca F; Martin AL; Mesleard C; Lemonnier J; de Cremoux P
Breast Cancer Res Treat; 2013 Jun; 139(3):789-800. PubMed ID: 23780683
[TBL] [Abstract][Full Text] [Related]
6. Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Norton N; Fox N; McCarl CA; Tenner KS; Ballman K; Erskine CL; Necela BM; Northfelt D; Tan WW; Calfa C; Pegram M; Colon-Otero G; Perez EA; Clynes R; Knutson KL
Breast Cancer Res; 2018 Jun; 20(1):52. PubMed ID: 29898752
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer.
Musolino A; Naldi N; Dieci MV; Zanoni D; Rimanti A; Boggiani D; Sgargi P; Generali DG; Piacentini F; Ambroggi M; Cagossi K; Gianni L; Sarti S; Bisagni G; Ardizzoni A; Conte PF; Guarneri V
Pharmacogenomics J; 2016 Oct; 16(5):472-7. PubMed ID: 27378608
[TBL] [Abstract][Full Text] [Related]
8. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial.
Caparica R; Ma Y; De Angelis C; Richard F; Desmedt C; Awada A; Piccart M; Perez EA; Moreno-Aspitia A; Badve S; Thompson EA; de Azambuja E
Clin Breast Cancer; 2022 Jun; 22(4):308-318. PubMed ID: 34980541
[TBL] [Abstract][Full Text] [Related]
9. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
Kjersem JB; Skovlund E; Ikdahl T; Guren T; Kersten C; Dalsgaard AM; Yilmaz MK; Fokstuen T; Tveit KM; Kure EH
BMC Cancer; 2014 May; 14():340. PubMed ID: 24884501
[TBL] [Abstract][Full Text] [Related]
10. Fcgamma receptor gene polymorphisms in Japanese patients with systemic lupus erythematosus: contribution of FCGR2B to genetic susceptibility.
Kyogoku C; Dijstelbloem HM; Tsuchiya N; Hatta Y; Kato H; Yamaguchi A; Fukazawa T; Jansen MD; Hashimoto H; van de Winkel JG; Kallenberg CG; Tokunaga K
Arthritis Rheum; 2002 May; 46(5):1242-54. PubMed ID: 12115230
[TBL] [Abstract][Full Text] [Related]
11. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.
Perez EA; Dueck AC; McCullough AE; Chen B; Geiger XJ; Jenkins RB; Lingle WL; Davidson NE; Martino S; Kaufman PA; Kutteh LA; Sledge GW; Harris LN; Gralow JR; Reinholz MM
J Clin Oncol; 2013 Jun; 31(17):2115-22. PubMed ID: 23650412
[TBL] [Abstract][Full Text] [Related]
12. Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.
Moreno-Aspitia A; Hillman DW; Dyar SH; Tenner KS; Gralow J; Kaufman PA; Davidson NE; Lafky JM; Reinholz MM; Lingle WL; Kutteh LA; Carney WP; Dueck AC; Perez EA
Cancer; 2013 Aug; 119(15):2675-82. PubMed ID: 23744760
[TBL] [Abstract][Full Text] [Related]
13. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.
Dueck AC; Reinholz MM; Geiger XJ; Tenner K; Ballman K; Jenkins RB; Riehle D; Chen B; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow J; Harris LN; Ingle JN; Lingle WL; Perez EA
Clin Cancer Res; 2013 Oct; 19(20):5798-807. PubMed ID: 23965903
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
15. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
Perez EA; Romond EH; Suman VJ; Jeong JH; Davidson NE; Geyer CE; Martino S; Mamounas EP; Kaufman PA; Wolmark N
J Clin Oncol; 2011 Sep; 29(25):3366-73. PubMed ID: 21768458
[TBL] [Abstract][Full Text] [Related]
16. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.
Perez EA; Thompson EA; Ballman KV; Anderson SK; Asmann YW; Kalari KR; Eckel-Passow JE; Dueck AC; Tenner KS; Jen J; Fan JB; Geiger XJ; McCullough AE; Chen B; Jenkins RB; Sledge GW; Winer EP; Gralow JR; Reinholz MM
J Clin Oncol; 2015 Mar; 33(7):701-8. PubMed ID: 25605861
[TBL] [Abstract][Full Text] [Related]
17. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.
Perez EA; Jenkins RB; Dueck AC; Wiktor AE; Bedroske PP; Anderson SK; Ketterling RP; Sukov WR; Kanehira K; Chen B; Geiger XJ; Andorfer CA; McCullough AE; Davidson NE; Martino S; Sledge GW; Kaufman PA; Kutteh LA; Gralow JR; Harris LN; Ingle JN; Lingle WL; Reinholz MM
J Clin Oncol; 2011 Feb; 29(6):651-9. PubMed ID: 21245420
[TBL] [Abstract][Full Text] [Related]
18. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
19. Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Strefford JC; Nowicka M; Hargreaves CE; Burton C; Davies A; Ganderton R; Hiddemann W; Iriyama C; Klapper W; Latham KV; Martelli M; Mir F; Parker H; Potter KN; Rose-Zerilli MJJ; Sehn LH; Trněný M; Vitolo U; Bolen CR; Klein C; Knapp A; Oestergaard MZ; Cragg MS
Blood Adv; 2021 Aug; 5(15):2935-2944. PubMed ID: 34323957
[TBL] [Abstract][Full Text] [Related]
20. Association of Fcgamma receptor IIb polymorphism with susceptibility to systemic lupus erythematosus in Chinese: a common susceptibility gene in the Asian populations.
Chu ZT; Tsuchiya N; Kyogoku C; Ohashi J; Qian YP; Xu SB; Mao CZ; Chu JY; Tokunaga K
Tissue Antigens; 2004 Jan; 63(1):21-7. PubMed ID: 14651519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
